Ezra Cohen, MD, is Chief of the Division of Hematology‐Oncology, and Co‐Director of the San Diego Center for Precision Immunotherapy, Associate Director for Clinical Science, Associate Director for Translational Science, and leader of the Solid Tumor Therapeutics research program at Moores Cancer Center. He has made major contributions to targeted and immunotherapy. His research has received peer‐reviewed funding in the study of epidermal growth factor receptor inhibitors, cell therapy, and immunotherapy in head and neck cancer. Dr. Cohen has authored more than 200 papers and has presented his research at national and international meetings. He brings his expertise and preeminent reputation in head and neck cancer research and patient care to solid tumor therapeutics and has been the principal investigator on multiple studies of novel agents in head and neck cancer and other solid tumors in all phases of development including chemoprevention, phase I, II, and III trials. He has made major contributions to the understanding of critical signaling pathways, integration of novel agents into standard of care, and definition of mechanisms to overcome resistance to drug therapy. He completed a Hematology/Oncology fellowship at the University of Chicago and prior to his arrival in San Diego, Dr. Cohen was Co‐Director of the Head and Neck Cancer Program, Associate Director for Education and Program Director for the Hematology/Oncology Fellowship at the University of Chicago Comprehensive Cancer Center. He has also recently co‐developed a personalized neoantigen vaccine using unique cancer mutations to boost an anti‐tumor immune response.